



**EISAI TO ESTABLISH ORAL SOLID DOSE PRODUCTION FACILITY  
AT NEW SUZHOU PLANT IN CHINA**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Chinese

**[Notes to editors]**

**1. Outline of New Suzhou Plant**

Location: 168 Xingpu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China

Site area: Approximately 134,000 m<sup>2</sup>

(A) New Oral Solid Dose Production Facility (Scheduled for construction)

- Floor space: Approximately 20,900 m<sup>2</sup> / Three floors
- Main functions: Manufacturing, packaging, storage, etc.
- Scheduled for production: Methycobal, Aricept, Pariet and other products


(B) Parenteral Production Facility (Construction complete)

- Floor space: Approximately 3,300 m<sup>2</sup> / Two floors
- Scheduled for production: Methycobal injection

(C) New Administration Building (Scheduled for construction)

- Floor space: Approximately 2,280 m<sup>2</sup> / Two floors
- Main facilities: Offices, meeting rooms, cafeteria, etc.

(D) Distribution Warehouse (Previously established)



Artist's rendition of the new OSD facility and administration building at the new Suzhou Plant